PMID- 35859915
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220722
IS  - 1178-6973 (Print)
IS  - 1178-6973 (Electronic)
IS  - 1178-6973 (Linking)
VI  - 15
DP  - 2022
TI  - Successful Treatment of Relapsed Epstein-Barr Virus-Associated Hemophagocytic 
      Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report.
PG  - 3751-3756
LID - 10.2147/IDR.S372998 [doi]
AB  - BACKGROUND: Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis 
      (EBV-HLH) is a rare and aggressive disease with high mortality and poor 
      prognosis. To date, allogeneic hematopoietic stem cell transplantation 
      (allo-HSCT) remains the only way to cure EBV-HLH. However, relapse of EBV-HLH 
      after allo-HSCT is common and remains a major challenge. CASE PRESENTATION: A 
      22-year-old woman with persistent fever for a month presented to our center with 
      EBV-HLH. After induction of remission using two cycles of the L-DEP 
      (PEG-aspargase, liposomal doxorubicin, etoposide, and high-dose 
      methylprednisolone) regimen, the patient underwent an human leukocyte antigen 
      (HLA)-identical sibling allo-HSCT. However, she experienced disease relapse soon 
      after the procedure, and none of the possible treatment options achieved a 
      sustained response. Finally, she received a sintilimab injection and achieved 
      complete resolution of EBV-HLH. CONCLUSION: We summarize a case of relapsed 
      EBV-HLH after allo-HSCT that was successfully treated with a programmed cell 
      death protein-1 (PD-1) antibody. Further studies are needed to determine whether 
      PD-1 blockade has therapeutic potential for relapsed EBV-HLH after allo-HSCT.
CI  - (c) 2022 Pi et al.
FAU - Pi, Yubo
AU  - Pi Y
AUID- ORCID: 0000-0002-8971-5517
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, 100050, People's Republic of China.
FAU - Wang, Jingshi
AU  - Wang J
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, 100050, People's Republic of China.
FAU - Wang, Zhao
AU  - Wang Z
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, 100050, People's Republic of China.
LA  - eng
PT  - Case Reports
DEP - 20220713
PL  - New Zealand
TA  - Infect Drug Resist
JT  - Infection and drug resistance
JID - 101550216
PMC - PMC9289273
OTO - NOTNLM
OT  - Epstein-Barr virus
OT  - PD-1 antibody
OT  - allogeneic hematopoietic stem cell transplantation
OT  - graft-versus-host disease
COIS- The authors declare no conflicts of interest in this work.
EDAT- 2022/07/22 06:00
MHDA- 2022/07/22 06:01
PMCR- 2022/07/13
CRDT- 2022/07/21 02:21
PHST- 2022/05/10 00:00 [received]
PHST- 2022/07/07 00:00 [accepted]
PHST- 2022/07/21 02:21 [entrez]
PHST- 2022/07/22 06:00 [pubmed]
PHST- 2022/07/22 06:01 [medline]
PHST- 2022/07/13 00:00 [pmc-release]
AID - 372998 [pii]
AID - 10.2147/IDR.S372998 [doi]
PST - epublish
SO  - Infect Drug Resist. 2022 Jul 13;15:3751-3756. doi: 10.2147/IDR.S372998. 
      eCollection 2022.